CCT for Comprehensive Risk Stratification Following STEMI

Summary

The CT-STEMI study aims to evaluate a comprehensive cardiac computed tomography (CCT) protocol for assessing the risk of heart failure (HF), life-threatening arrhythmias (LTA), and atherothrombotic events following ST-elevation myocardial infarction (STEMI). This multicenter, prospective study has three main objectives:

1. Comparing the diagnostic accuracy of the comprehensive CCT protocol with cardiac magnetic resonance (CMR), considered the non-invasive gold standard.
2. Determining the prognostic value of CCT in assessing myocardial tissue adverse features related to STEMI.
3. Evaluating the atherosclerotic burden in patients with post-acute STEMI.

Two hundred patients will undergo both CCT and CMR in the post-acute phase, and their follow-up will focus on monitoring HF, LTA, and ischemic events. The CT-STEMI study represents the first attempt to assess the potential of CCT in providing a comprehensive risk assessment following STEMI in a large contemporary population. The findings of this study have the potential to revolutionize post-STEMI risk stratification practices.

Conditions

• Myocardial Infarction

Interventions

DIAGNOSTIC_TEST

Cardiac Computed Tomography

A comprehensive CCT protocol will be performed in the post-acute phase of STEMI. Specifically, the CCT protocol will include a pre-contrast scan and an angiographic scan ( also set up to assess ventricular volume and function) followed by late contrast enhancement scan.

DIAGNOSTIC_TEST

Cardiac Magnetic Resonance

A comprehensive CMR protocol will be performed in the post-acute phase of STEMI. Specifically, the CMR protocol is designed for morpho-functional analysis and tissue characterisation (including assessment of late gadolinium enhancement and mapping). CMR will be considered the gold standard.

Sponsors & Collaborators

• A.O.U. Città della Salute e della Scienza - Molinette Hospital

  collaborator OTHER

• Istituto Auxologico Italiano

  collaborator OTHER

• University of Messina

  collaborator OTHER

• Ministry of Health, Italy

  collaborator OTHER_GOV

• University of Turin, Italy

  lead OTHER

Principal Investigators

• Marco Gatti, M.D. · University of Turin, Italy

Study Design

Allocation

NA

Purpose

DIAGNOSTIC

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2023-11-08

Primary Completion

2026-04-30

Completion

2026-04-30

Countries

• Italy

Study Locations